Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Bisi · SciRah

Researcher profile · Semantic Scholar

J. Bisi

Share profile

J. Bisi — researcher profile on SciRah

h-index: 19
Works: 37
Citations: 3,868

Most-cited papers

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis.
J. Holt, G. Luo, A. Billin, J. Bisi +8 more
2003Genes & Development729 citations Open access
Semantic Scholar
CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation
Jiehui Deng, Eric S. Wang, R. Jenkins, Shuai Li +43 more
2017Cancer Discovery619 citations Open access
Semantic Scholar
Antisense and antigene properties of peptide nucleic acids.
J. Hanvey, N. Peffer, J. Bisi, S. A. Thomson +6 more
1992Science472 citations
Semantic Scholar
PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2
Shutong Yang, C. Kuo, J. Bisi, Myung K. Kim
2002Nature Cell Biology256 citations
Semantic Scholar
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
P. Roberts, J. Bisi, J. Strum, A. Combest +6 more
2012Journal of the National Cancer Institute252 citations Open access
Semantic Scholar
Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line
D. Welch, J. Bisi, B. Miller, D. Conaway +6 more
1991International Journal of Cancer190 citations
Semantic Scholar
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
W. Xia, J. Bisi, J. Strum, Lei-Hua Liu +10 more
2006Cancer Research163 citations Open access
Semantic Scholar
An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.
M. Bonham, Stephen C. Brown, A. Boyd, Pamela H. Brown +11 more
1995Nucleic Acids Research156 citations Open access
Semantic Scholar
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
Shenghui He, P. Roberts, J. Sorrentino, J. Bisi +9 more
2017Science Translational Medicine155 citations Open access
Semantic Scholar
Strand-invasion of duplex DNA by peptide nucleic acid oligomers.
N. Peffer, J. Hanvey, J. Bisi, S. A. Thomson +3 more
1993Proceedings of the National Academy of Sciences of the United States of America151 citations Open access
Semantic Scholar
Upstream stimulatory factor regulates expression of the cell cycle-dependent cyclin B1 gene promoter
J. Cogswell, M. Godlevski, M. Bonham, J. Bisi +1 more
1995Molecular and Cellular Biology129 citations Open access
Semantic Scholar
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
J. Bisi, J. Sorrentino, P. Roberts, Francis X. Tavares +1 more
2016Molecular Cancer Therapeutics114 citations
Semantic Scholar
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Catherine Dietrich, Alec Trub, Antonio Ahn, Michael Taylor +13 more
2023Cancer Discovery108 citations Open access
Semantic Scholar
Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription.
P. Delerive, C. Galardi, J. Bisi, E. Nicodeme +1 more
2004Molecular Endocrinology98 citations Open access
Semantic Scholar
Human tumor suppressor ARF impedes S-phase progression independent of p53.
W. Yarbrough, M. Bessho, A. Zanation, J. Bisi +1 more
2002Cancer Research63 citations
Semantic Scholar
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
J. Bisi, J. Sorrentino, Jamie L. Jordan, David D. Darr +3 more
2017OncoTarget49 citations Open access
Semantic Scholar
PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.
C. Nofziger, K. Brown, Chari D. Smith, W. Harrington +8 more
2009AJP - Renal Physiology43 citations
Semantic Scholar
Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays.
L. Parton, F. Diraison, S. E. Neill, Sujoy Ghosh +4 more
2004American Journal of Physiology. Endocrinology and Metabolism43 citations
Semantic Scholar
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Kaitlyn J. Andreano, S. Wardell, Jennifer G. Baker, Taylor K. Desautels +14 more
2020Breast Cancer Research and Treatment40 citations Open access
Semantic Scholar
Abstract 5641: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer
S. Wardell, Alexander P. Yllanes, Jennifer G. Baker, R. Baldi +5 more
201713 citations
Semantic Scholar
Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors
Claire R. Hall, J. Bisi, J. Strum
2019Molecular and Cellular Biology / Genetics6 citations
Semantic Scholar
First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.
R. Tiessen, P. Roberts, J. Sorrentino, H. White +5 more
20155 citations
Semantic Scholar
Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression.
P. Roberts, H. White, J. Sorrentino, H. Tadema +7 more
20153 citations
Semantic Scholar
PPAR (cid:1) agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line
C. Nofziger, K. Brown, Chari D. Smith, W. Harrington +8 more
20093 citations
Semantic Scholar
Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers
Alec G. Trub, J. Bisi, Catherine A. Dietrich, Michael Taylor +3 more
2023Cancer Research2 citations
Semantic Scholar
TREATMENT OF EGFR-DRIVEN CANCER WITH FEWER SIDE EFFECTS
J. Sorrentino, J. Strum, J. Bisi, A. Beelen
20182 citations
Semantic Scholar
P2.03a-048 The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth: Topic: Clinical Trials
I. Guijarro, A. Poteete, R. Ferrarotto, W. Denning +8 more
20171 citations Open access
Semantic Scholar
G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
P. Roberts, Shenghui He, G. Schvartsman, Tejas Patil +10 more
20161 citations
Semantic Scholar
Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors
J. Sorrentino, J. Bisi, P. Roberts, J. Strum
20161 citations
Semantic Scholar
The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.
I. Guijarro, W. Denning, R. Ferrarotto, A. Poteete +8 more
20161 citations
Semantic Scholar
Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy
J. Sorrentino, Shenghui He, J. Bisi, P. Roberts +2 more
20151 citations
Semantic Scholar
Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies
J. Bisi, H. White, J. Sorrentino, P. Roberts +1 more
20151 citations
Semantic Scholar
Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status
Hailey E. Brighton, Claire R. Hall, Kerry A. Dillon, J. Bisi +1 more
2019Molecular and Cellular Biology / Genetics0 citations
Semantic Scholar
Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer
J. Sorrentino, D. Freed, J. Bisi, J. Strum +1 more
2018Molecular and Cellular Biology / Genetics0 citations
Semantic Scholar
Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer
P. Roberts, D. Darr, J. Bisi, J. Strum
20140 citations
Semantic Scholar
Novel Therapeutics in Renal Diseases CDK 4 / 6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury
Derek P. DiRocco, J. Bisi, P. Roberts, J. Strum +3 more
20140 citations
Semantic Scholar
RNA Interference Technology: RNA interference technology in the discovery and validation of druggable targets
N. J. Clarke, J. Bisi, C. Creasy, M. Dush +4 more
20050 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Strum×23
Invite
J. Strum — researcher profile on SciRah
P. Roberts×16
Invite
P. Roberts — researcher profile on SciRah
J. Sorrentino×15
Invite
J. Sorrentino — researcher profile on SciRah
N. Sharpless×6
Invite
N. Sharpless — researcher profile on SciRah

×6

Invite

R. Malik — researcher profile on SciRah

Kwok-Kin Wong×3

Invite

Kwok-Kin Wong — researcher profile on SciRah

Invite

J. Hanvey — researcher profile on SciRah

S. A. Thomson×3

Invite

S. A. Thomson — researcher profile on SciRah

Invite

L. Babiss — researcher profile on SciRah

Invite

Shenghui He — researcher profile on SciRah

Invite

R. Tiessen — researcher profile on SciRah

Karenann M. Makhuli×3

Invite

Karenann M. Makhuli — researcher profile on SciRah